Article

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia

2026-01-24

Abstract excerpt

Post-treatment measurable residual disease (MRD) in acute myeloid leukemia (AML) patients is associated with adverse clinical outcomes. Validated molecular methods for AML MRD are preferable to flow cytometry assays but are not available for all patients. The limit of detection (LOD) of next-generation sequencing (NGS) assays for single nucleotide variants is restricted by technical error rates. Structural alterat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5be556ef-2ccd-5f94-84c7-3489f4635fea
DOI: 10.64898/2026.01.22.26343677

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid LeukemiaDOI 10.64898/2026.01.22.26343677Read

Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia – a proof-of- concept studySemantic proximity Read

Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring.Semantic proximity Read

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic LeukemiaSemantic proximity Read

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemiaSemantic proximity Read

Identification and Use of Personalized Genomic Markers for Monitoring Circulating Tumor DNA.Semantic proximity Read

Advances in DNA/RNA Sequencing and Their Applications in Acute Myeloid Leukemia (AML)Semantic proximity Read

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read

Droplet Digital PCR for Oncogenic KMT2A Fusion DetectionSemantic proximity Read

Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.Semantic proximity Read

Analytical Evaluation of Whole Genome Sequencing for Acute Myeloid LeukemiaSemantic proximity Read

Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid CancersSemantic proximity Read